Articles tagged "Kidney transplantation"

2019 American Transplant Congress
What’s in a High Dose? An Analysis of Tacrolimus Pharmacokinetic Parameters in Rapid Metabolizers
P. West-Thielke¹, A. Maldonado², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, D. Brennan⁴
¹University of Illinois, Chicago, Chicago, IL, ²Vidant Medical Center, Greenville, NC, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: CYP3A5*1 expressers exhibit differences in immediate-release tacrolimus (IR-Tac) PK and require higher doses of IR-Tac to maintain therapeutic trough concentrations. LCP-Tacrolimus (LCPT) demonstrates a…
2019 American Transplant Congress
Apolipoprotein L1 Genotyping in Potential African American Living Kidney Donors
P. Gudsoorkar, M. Anand, T. Kaur, S. Shah, S. Bumb, A. Govil, B. G. Abu Jawdeh
U.Cincinnati, Cincinnati, OH
*Purpose: African Americans(AA) account for 13% of the US population, yet compose more than one third of dialysis patients. Inheriting two Apolipoprotein L1 gene (APOL1)…
2019 American Transplant Congress
Measuring and Monitoring Disparities in Access to Kidney Transplantation Associated with Being Listed for a Multi-Organ Transplant (MOT)
D. E. Stewart, C. A. Custer, A. M. Robinson, A. R. Wilk
UNOS, Richmond, VA
*Purpose: In 2018, the OPTN published a new methodology for measuring and monitoring disparities in access to deceased donor kidney (KI) transplantation (Tx) among kidney-alone…
2019 American Transplant Congress
Super-resolution Evaluation Of The Glomerular Basement Membrane Changes In The Course Of Transplant Glomerulopathy
D. Hammad, J. H. Miner, T. Alhamad, H. Suleiman
Washinton University in St. Louis, St. Louis, MO
*Purpose: Transplant Glomerulopathy (TG) is a histologic entity that affects around 20% of kidney allografts by 5 years post transplantation and results in a significant…
2019 American Transplant Congress
Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies
K. Louis¹, D. Viglietti¹, D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Zeevi², A. Loupy¹, C. Lefaucheur¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Switching from CNI- to Belatacept-based regimen has been associated with improved graft function in low-immunologic risk kidney recipients. We investigated the efficacy and safety…
2019 American Transplant Congress
Standardizing Blood Pressure Measurement across 17 Pediatric Transplant Centers: The Improving Renal Outcomes Collaborative
M. E. Seifert¹, R. Garro², R. P. George², G. Barletta³, C. W. Belsha⁴, A. Chaudhuri⁵, J. W. Goebel⁶, L. Wickman⁷, D. Matossian⁸, J. Misurac⁹, C. Nailescu¹⁰, C. R. Nguyen¹¹, M. Pearl¹², A. Pollack¹³, C. S. Pruette¹⁴, P. Singer¹⁵, P. S. Verghese¹⁶, B. A. Warady¹⁷, D. S. Dahale¹⁸, D. K. Hooper¹⁸
¹University of Alabama, Birmingham, AL, ²Emory University, Atlanta, GA, ³Phoenix Children's Hospital, Phoenix, AZ, ⁴Saint Louis University, St. Louis, MO, ⁵Stanford University, Stanford, CA, ⁶Children's Hospital Colorado, Aurora, CO, ⁷Michigan Medicine, Ann Arbor, MI, ⁸Lurie Children's Hospital, Chicago, IL, ⁹University of Iowa, Iowa City, IA, ¹⁰Riley Hospital For Children, Indianapolis, IN, ¹¹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ¹²UCLA Mattel Children’s Hospital, Los Angeles, CA, ¹³Seattle Children's Hospital, Seattle, WA, ¹⁴Johns Hopkins University, Baltimore, MD, ¹⁵Cohen Children's Medical Center, New Hyde Park, NY, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Children's Mercy Kansas City, Kansas City, MO, ¹⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: We report efforts from the Improving Renal Outcomes Collaborative (IROC) to standardize appropriate BP measurement across 17 pediatric kidney transplant centers.*Methods: 17 centers participated…
2019 American Transplant Congress
Actions Speak Louder Than Labs – The Impact of Dialysis Compliance on Posttransplant Outcomes
D. Sawinski¹, H. Lindner², J. Schults³, J. Locke⁴, P. Reese¹
¹Hospital of the U of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL
*Purpose: Non-adherence is a modifable risk factor for poor posttransplant outcomes. While the factors contributing to posttransplant non-adherence are complex, noncompliance with the dialysis prescription…
2019 American Transplant Congress
Higher Level of Social Support is Associated with Higher Likelihood of Pursuit of Living Donor Kidney Transplant (LDKT)
T. Ahmed¹, S. Dano¹, Z. Zhou¹, I. Unarain¹, M. Saqib¹, V. Li¹, Y. Khoo¹, M. Novak², I. Mucsi¹
¹Multi-Organ Transplant Program and Division of Nephrology, University Health Network, Toronto, ON, Canada, ²Centre for Mental Health, University Health Network, Toronto, ON, Canada
*Purpose: LDKT is the optimal treatment for many patients with End Stage Kidney Disease (ESKD) , offering better clinical outcomes and quality of life. Studies…
2019 American Transplant Congress
Tissue Resident Memory T Cells in Murine Renal Transplantation
K. Abou-Daya, D. Zhao, R. Tieu, A. Williams, M. Oberbarnscheidt, F. Lakkis
Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: The newly identified tissue resident subset of memory T cells (TRM) provides immune surveillance in the tissue and first response against infections. They are…
2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
D. Cibrik¹, P. West-Thielke², S. J. Patel³, D. R. Stevens⁴, U. Meier-Kriesche⁴
¹University of Kansas Medical Center, Kansas City, KS, ²University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, ³Veloxis Pharmaceuticals, Cary, NC, ⁴Veloxis Pharmaceuticals Inc., Cary, NC
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…